1 withdrawn. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
Follow Grey Zone Lymphoma: new trials by email Literature Review of Grey Zone Lymphoma trials Research Report on Grey Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Brentuximab, Bendamustine, Rituximab - Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma | Phase 2 | Withdrawn | University of Arizona | 2015-12-16 | 2017-05-19 |
Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1)
Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, B-Cell (1) · Leukemia, Lymphoid (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1) · Neoplasms (1)
Bendamustine Hydrochloride (1) · Brentuximab Vedotin (1) · Rituximab (1)
United States (1)